| Characteristics | FDC (n = 795) | FEC (n = 712) | Monotherapy (n = 7169) | P* |
|---|---|---|---|---|
| Female sex, n (%) | 373 (46.9) | 442 (62.1) | 3878 (44.7) | <.001 |
| Age at index (years) | 52.9 (12.6) | 61.9 (12.9) | 53.8 (13.4) | <.001 |
| BMI (kg/m2) | 31.9 (7.2) | 30.4 (6.9) | 30.6 (6.8) | <.001 |
| Index systolic BP (mm Hg) | 153.8 (16.5) | 147.8 (16.4) | 148.2 (14.7) | <.001 |
| Index diastolic BP (mm Hg) | 94.3 (11.1) | 85.9 (12.2) | 90.4 (10.6) | <.001 |
| CKD, n (%) | 54 (6.8) | 188 (26.4) | 612 (7.1) | <.001 |
| Diabetes, n (%) | 66 (8.3) | 168 (23.6) | 1091 (12.6) | <.001 |
| Hyperlipidemia, n (%) | 251 (31.6) | 209 (29.4) | 2381 (27.4) | .09 |
| Hypertension, n (%) | 594 (74.7) | 456 (64.0) | 4280 (49.3) | <.001 |
| Follow-up duration (months) | 6.2 (3.8) | 6.7 (3.9) | 6.3 (3.9) | .02 |
| Number of clinic visits | 3.0 (2.8) | 4.2 (3.8) | 3.9 (3.4) | <.001 |
Data are mean (standard deviation) unless otherwise indicated.
↵* P values were from analysis of variance (ANOVA) or logistic regression and test the overall effect across the three treatment strategies.
BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; FDC, fixed-dose combination; FEC, free-equivalent combination.